Overcoming Resistance to Targeted Therapies in Cancer

Carolien Boeckx, Jolien Van den Bossche, Ines De Pauw, Marc Peeters, Filip Lardon, Marc Baay, An Wouters, The hypoxic tumor microenvironment and drug resistance against EGFR inhibitors: preclinical study in cetuximab-sensitive head and neck squamous cell carcinoma cell lines BMC Research Notes. ,vol. 8, pp. 203- 203 ,(2015) , 10.1186/S13104-015-1197-6

Katharina Feldinger, Daniele Generali, Gabriela Kramer-Marek, Merel Gijsen, Tzi Bun Ng, Jack Ho Wong, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Ji-Liang Li, Esther Bridges, Helen Turley, Russell Leek, Ioannis Roxanis, Jacek Capala, Gillian Murphy, Adrian L. Harris, Anthony Kong, ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer Oncotarget. ,vol. 5, pp. 6633- 6646 ,(2014) , 10.18632/ONCOTARGET.1955

Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J Carl Barrett, Pasi A Jänne, Geoffrey R Oxnard, Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M Nature Medicine. ,vol. 21, pp. 560- 562 ,(2015) , 10.1038/NM.3854

Zhengyan Yang, Liang Guo, Dan Liu, Limin Sun, Hongyu Chen, Que Deng, Yanjun Liu, Ming Yu, Yuanfang Ma, Ning Guo, Ming Shi, Acquisition of resistance to trastuzumab in gastric cancer cells is associated with activation of IL-6/STAT3/Jagged-1/Notch positive feedback loop Oncotarget. ,vol. 6, pp. 5072- 5087 ,(2015) , 10.18632/ONCOTARGET.3241

Andrei Ougolkov, Kaname Yamashita, Vladimir Bilim, Yutaka Takahashi, Masayoshi Mai, Toshinari Minamoto, Abnormal expression of E-cadherin, β-catenin, and c-erbB-2 in advanced gastric cancer: Its association with liver metastasis International Journal of Colorectal Disease. ,vol. 18, pp. 160- 166 ,(2003) , 10.1007/S00384-002-0427-2

Chengguang Zhao, Hui Xiao, Xiaojuan Wu, Chenglong Li, Guang Liang, Shulin Yang, Jiayuh Lin, Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells Oncotarget. ,vol. 6, pp. 14472- 14487 ,(2015) , 10.18632/ONCOTARGET.3991

Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)

M. Peeters, G. Kafatos, A. Taylor, V.M. Gastanaga, K.S. Oliner, G. Hechmati, J.-H. Terwey, J.H. van Krieken, Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials. European Journal of Cancer. ,vol. 51, pp. 1704- 1713 ,(2015) , 10.1016/J.EJCA.2015.05.017

Louise J Barber, Shahneen Sandhu, Lina Chen, James Campbell, Iwanka Kozarewa, Kerry Fenwick, Ioannis Assiotis, Daniel Nava Rodrigues, Jorge S Reis-Filho, Victor Moreno, Joaquin Mateo, L Rhoda Molife, Johann De Bono, Stan Kaye, Christopher J Lord, Alan Ashworth, Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor. The Journal of Pathology. ,vol. 229, pp. 422- 429 ,(2013) , 10.1002/PATH.4140

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, Chris Arthur, Kerry Taylor, Richard Herrmann, Kevin P. Lynch, Timothy P. Hughes, High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. ,vol. 99, pp. 3472- 3475 ,(2002) , 10.1182/BLOOD.V99.9.3472